COVID-19 patients in the US will have greater access to convalescent blood plasma therapy after the US Food and Drug Administration granted the treatment emergency use authorization (EUA) – with President Donald Trump proclaiming the treatment a “powerful therapy” with “an incredible rate of success.”
The EUA was announced on 23 August, and is based on an expanded-access program at Mayo Clinic funded by the...






